Status:
UNKNOWN
Intravenous Immunoglobulin for Unverricht-Lundborg Disease.
Lead Sponsor:
Azienda Socio Sanitaria Territoriale di Mantova
Conditions:
Unverricht-Lundborg Disease
Eligibility:
MALE
18-25 years
Phase:
PHASE3
Brief Summary
Single patient randomized double blind trial to assess whether intravenous immunoglobulin can improve the clinical outcome of a case suffering from Unverricht-Lundborg disease.
Detailed Description
Single patient randomized double blind trial to assess whether intravenous immunoglobulin can improve the clinical outcome of a case suffering from Unverricht-Lundborg disease (clinical and genetic di...
Eligibility Criteria
Inclusion
- Malattia di Unverricht-Lundborg (genetic diagnosis)
Exclusion
- Contraindications to intravenous immunoglobulin
Key Trial Info
Start Date :
December 9 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2017
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03351569
Start Date
December 9 2015
End Date
December 30 2017
Last Update
November 27 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.